The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksASH.L Regulatory News (ASH)

  • There is currently no data for ASH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Results

26 Jan 2010 07:00

RNS Number : 1025G
Ashley House PLC
26 January 2010
 



Press Release

26 January 2010

Ashley House plc

Ashley House plc ("Ashley House" or the "Company") the Primary Care infrastructure specialist today announces its interim results for the six months ended 31 October 2009.

HIGHLIGHTS

FINANCIAL

- Revenue up 64% to £13.3m (2008: £8.1m)

- Pre-Tax Profit up 96% to £1.5m (2008: £0.75m)

- Earnings per share up 57% to 2.2p (2008: 1.4p) 

- Interim Dividend 1.0p per share (2008: 0.0p)

- Net Assets £38.4m (2008: £33.0m)

OPERATIONAL

- Successful acquisition of Sapphire Primary Care Developments from Lloyds Pharmacy

- Strong forward pipeline of £238 m of project value over next 2 years

 

Ashley House plc Chairman Sir William Wells said:

 

"The first half of the year has shown a marked improvement on the same period last year and we are encouraged by this performance. The fundamentals of the business remain sound and in the medium term we believe that the outlook is still positive as the NHS strives to achieve greater efficiency through service rationalisation and modernisation. 

"However, the shorter term outlook for the Primary Care Infrastructure market remains uncertain as Primary Care Trusts re-examine budgets and plan for future savings against a backdrop of political uncertainty. Whilst timings of projects in the near term may be affected we are confident that our business with its strong market position in a niche with good fundamentals will continue to deliver in the medium term."

  Enquiries:

Ashley House plc

Tel:

01628 600340

Jonathan Holmes, Chief Executive

Bruce Walker, Finance Director

 

 

 

 

 

Citigate Dewe Rogerson

Tel:

020 7638 9571

Sarah Gestetner Ged Brumby

 

 

 

 

 

Numis Securities (Nominated Adviser and broker to Ashley House)

Tel:

020 7260 1000

David Poutney / Oliver Cardigan / Simon Blank

 

 

Chairman's Statement

Results

The first six months of the financial year have shown some positive progress. Turnover has risen 64% to £13.3m (2008:£8.1m), pre-tax profit has increased 96% to £1.5m (2008: £0.75m) and earnings per share has advanced 57% to 2.2p per share (2008:1.4p).  The Board is pleased to re-instate the interim dividend at 1p per share (2008:0p).

Trading

Trading during the period has shown an improvement on the prior year with good progress being made on a number of schemes. However, the shorter term outlook for the Primary Care Infrastructure market is uncertain. Whilst the main political parties are making statements that they will protect the NHS, our experience is that some Primary Care Trusts are re-examining their budgets and planning for significant savings. In the trading statement we released on 16 November 2009, we identified 5 new schemes which we anticipated to take onto site before Christmas. Unfortunately none of these schemes has yet commenced construction due in some cases to the Strategic Health Authority re-examining PCTs' business cases notwithstanding previous approvals from the Primary Care Trusts themselves. We are assured by the relevant PCTs that these projects will enter the build phase in the coming weeks but specific start dates are still uncertain.

As a result we have taken action to reduce our overhead costs closing offices in Bath, Llanellen, Newcastle and Worcester with the unfortunate but necessary loss of some staff. Cost cutting initiatives have removed c. £1m on an annualised basis from the Company's overhead.

As we take the business forward our strategy is to develop our recurring revenue streams from activities such as asset & estate management, some of which will come from managing "Whole Estates" of health trusts.  Furthermore, work in similar sectors such as community and elderly care is also being brought forward.  This should have the benefit of diversifying the client base beyond PCTs to other public and private sector end users.

Acquisition

As reported on 20th November 2009, we completed the acquisition of Sapphire Primary Care Developments Ltd from Lloyds Pharmacy (Admenta Holdings Ltd).  As a consequence we now have a stronger presence in the Midlands, a new capability in Scotland, a further pipeline of schemes and a 25% interest in a pharmacy joint venture.  It is anticipated that this JV should result in an increasing long term, recurring revenue stream as the new pharmacies come on stream and move into profit.  We have one such venture with Lloyds Pharmacy trading and have a further 6 with planning consent with an internal target of 20 within the next 3 years.  We were pleased with the support for the small placing undertaken at the time of the transaction to provide working capital for this acquisition.  Since completing the deal we have agreed to sell the minority NHS LIFT investment interests acquired with Sapphire to the other existing consortium partners as we had planned to do.  These interests generated small levels of investment income and gave no further opportunity to provide other services.

Outlook

Whilst the medium term outlook is still positive as the NHS strives to achieve greater efficiency through service rationalisation and modernisation in the shorter term there is considerable uncertainty.

Ashley House maintains a strong market position in a niche with good fundamentals. Our pipeline of schemes upon which we expect to recognise revenues in the next 2 years stands at £238m at the end of January. The devolvement of services from acute sector into primary and community facilities is supported by all political parties and has demonstrably improved patient care and access in many sectors.

Sir William Wells

Chairman

Ashley House plc

25 January 2010

Independent review report to Ashley House plc

Introduction

We have been engaged by the company to review the financial information in the half-yearly financial report for the six months ended 31 October 2009 which comprises the condensed consolidated interim income statement, condensed consolidated interim balance sheet, condensed consolidated interim statement of changes in equity, condensed consolidated interim cash flow statement and notes 1 to 7. We have read the other information contained in the half yearly financial report which comprises only the Chairman's statement and considered whether it contains any apparent misstatements or material inconsistencies with the information in the condensed set of financial statements.

This report is made solely to the company in accordance with guidance contained in ISRE (UK and Ireland) 2410, 'Review of Interim Financial Information performed by the Independent Auditor of the Entity'. Our review work has been undertaken so that we might state to the company those matters we are required to state to them in a review report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company, for our review work, for this report, or for the conclusion we have formed.

Directors' responsibilities

The half-yearly financial report is the responsibility of, and has been approved by, the directors. The AIM rules of the London Stock Exchange require that the accounting policies and presentation applied to the financial information in the half-yearly financial report are consistent with those which will be adopted in the annual accounts having regard to the accounting standards applicable for such accounts.

As disclosed in note 2, the annual financial statements of the group are prepared in accordance with IFRSs as adopted by the European Union. The financial information in the half-yearly financial report has been prepared in accordance with the basis of preparation in note 2.

Our responsibility 

Our responsibility is to express to the company a conclusion on the financial information in the half-yearly financial report based on our review. 

Scope of review 

We conducted our review in accordance with International Standard on Review Engagements (UK and Ireland) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Auditing Practices Board for use in the United Kingdom. A review of interim financial information consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing (UK and Ireland) and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. 

Conclusion 

Based on our review, nothing has come to our attention that causes us to believe that the financial information in the half-yearly financial report for the six months ended 31 October 2009 is not prepared, in all material respects, in accordance with the basis of accounting described in note 2.

GRANT THORNTON UK LLP

AUDITOR

OXFORD

25 January 2010

Condensed consolidated interim income statement

Unaudited

Unaudited

Audited

6 months

to 31

October

2009

6 months

to 31

October

2008

Year to

30 April

2009

Note

£000

£000

£000

Revenue

13,345

8,119

23,834

Cost of sales

(9,055)

(4,884)

(12,575)

Gross profit

4,290

3,235

11,259

Administrative expenses

(2,801)

(2,482)

(5,726)

Depreciation, amortisation and impairment

of non-financial assets

(55)

(97)

(114)

Operating profit

1,434

656

5,419

Investment income

31

90

107

Profit before taxation

1,465

746

5,526

Income tax on profit

(412)

(202)

(1,361)

Profit for the period

1,053

544

4,165

Other comprehensive income

Fair value movement on available for sale

investment

341

(572)

(584)

Total comprehensive income/(expense) for the period

1,394

(28)

3,581

Earnings per share:

Basic earnings per share

5

2.22p

1.38p

10.01p

Diluted earnings per share

5

2.19p

1.32p

9.65p

Condensed consolidated interim balance sheet

Unaudited

Unaudited

Audited

31 October

2009

31 October

2008

30 April

2009

Note

£000

£000

£000

ASSETS

Non-current assets

Goodwill

270

270

270

Other intangible assets

24,800

44,390

24,800

Property, plant and equipment

194

258

213

Available for sale investments

1,079

749

738

Deferred tax asset

210

513

210

26,553

46,180

26,231

Current assets

Work in progress

1,402

1,318

1,361

Trade and other receivables

21,771

11,095

18,778

Cash and cash equivalents

4

2,665

2,412

3,314

25,838

14,825

23,453

Total assets

52,391

61,005

49,684

LIABILITIES

Current liabilities

Trade and other payables

(8,558)

(5,530)

(7,664)

Bank borrowings and overdrafts

(2,000)

(802)

-

Current income tax

(1,319)

(550)

(1,219)

(11,877)

(6,882)

(8,883)

Non-current liabilities

Bank borrowings

(2,127)

(2,118)

(2,127)

Deferred consideration

-

(19,000)

-

Total non-current liabilities

(2,127)

(21,118)

(2,127)

Total liabilities

(14,004)

(28,000)

(11,010)

Net assets

38,387

33,005

38,674

EQUITY

Share capital

478

436

470

Share premium account

31,818

29,387

31,627

Share based payment reserve

614

793

608

Retained earnings

5,477

2,389

5,969

Total equity

38,387

33,005

38,674

Condensed consolidated interim statement of changes in equity

Share

capital

Share

Premium

account

Share based

Payment

reserve

Retained

earnings

Total

equity

£000

£000

£000

£000

£000

Balance at 1 May 2008

275

8,040

2,221

2,910

13,446

Dividends

-

-

-

(1,607)

(1,607)

Issue of share capital

161

21,347

-

-

21,508

Transfers on conversion of warrants

-

-

(1,114)

1,114

-

Transaction with owners

161

21,347

(1,114)

(493)

19,901

Other comprehensive income/(expense)

Profit on ordinary activities after tax

-

-

-

544

544

Fair value movement on available for sale investment

-

-

-

(572)

(572)

Movement on deferred tax

-

-

(314)

-

(314)

Total comprehensive expense for the period

-

-

(314)

(28)

(342)

Balance at 31 October 2008

436

29,387

793

2,389

33,005

Balance at 1 May 2008

275

8,040

2,221

2,910

13,446

Issue of share capital

195

23,587

-

-

23,782

Transfers on conversion of warrants

-

-

(1,085)

1,085

-

Dividends

-

-

-

(1,607)

(1,607)

Share-based payment charge

Transaction with owners

195

23,587

(996)

(522)

22,264

Other comprehensive income/(expense)

Profit on ordinary activities after tax

-

-

-

4,165

4,165

Fair value movement on available for sale investment

-

-

-

(584)

(584)

Movement on deferred tax

-

-

(617)

-

(617)

Total comprehensive (expense)/income for the year

-

-

(617)

3,581

2,964

Balance at 30 April 2009

470

31,627

608

5,969

38,674

Share

capital

Share

Premium

account

Share based

Payment

reserve

Retained

earnings

Total

equity

£000

£000

£000

£000

£000

Balance at 1 May 2009

470

31,627

608

5,969

38,674

Dividends

-

-

-

(1,886)

(1,886)

Issue of share capital

8

191

-

-

199

Share-based payment charge

-

-

6

-

6

Transaction with owners

8

191

6

(1,886)

(1,681)

Other comprehensive income

Profit on ordinary activities after tax

-

-

-

1,053

1,053

Fair value movement on available for sale investment

-

-

-

341

341

Total comprehensive income for the period 

-

-

-

1,394

1,394

Balance at 31 October 2009

478

31,818

614

5,477

38,387

Condensed consolidated interim cash flow statement

Unaudited

Unaudited

Audited

6 months to

31 October

2009

6 months to

31 October

2008

Year to

30 April

2009

£000

£000

£000

Operating activities

Profit before taxation

1,465

746

5,526

Adjustments for:

Depreciation

55

63

114

Loss on sale of fixed assets

-

2

-

Investment income

(31)

(90)

(107)

Share based payment charge

6

-

89

Operating cash flows before movements in working capital

1,495

721

5,622

(Increase) in work in progress

(41)

(59)

(102)

(Increase) in trade and other receivables

(2,994)

(307)

(6,064)

Increase/(decrease) in trade and other payables

894

(921)

920

Cash (used)/generated from operations

(646)

(566)

376

Income taxes paid

(312)

(905)

(1,395)

Net cash (used) in operating activities

(958)

(1,471)

(1,019)

Investing activities

Purchase of property, plant and equipment

(35)

(17)

(19)

Acquisition of interest in jointly controlled entities net of cash

-

(11,778)

(12,824)

Investment income

31

22

44

Interest received

-

68

63

Net cash (used) in investing activities

(4)

(11,705)

(12,736)

Financing activities

Proceeds from issue of share capital

199

9,508

11,782

Increase in bank loan

2,000

16

25

Dividends paid

(1,886)

(1,607)

(1,607)

Net cash from financing activities

313

7,917

10,200

Net (decrease) in cash and cash equivalents

(649)

(5,259)

(3,555)

Cash and cash equivalents at beginning of period 

3,314

6,869

6,869

Net Cash and cash equivalents at end of period

2,665

1,610

3,314

Notes to the condensed consolidated interim financial statements

1. Nature of operations and general information

Ashley House plc and subsidiaries' ('the Group') principal activities consist of the design and project management of primary care infrastructure construction and asset management.

Ashley House plc is the Group's ultimate parent company. It is incorporated and domiciled in Great BritainThe address of Ashley House plc's registered office, which is also its principal place of business, is The Priory, Stomp Road, Burnham, BuckinghamshireSL1 7LW. Ashley House plc's shares are listed on the Alternative Investment Market of the London Stock Exchange.

Ashley House's consolidated interim financial statements are presented in Pounds Sterling (£), which is also the functional currency of the parent company.

These consolidated condensed interim financial statements have been approved for issue by the Board of Directors on 25 January 2010.

The financial information set out in this interim report does not constitute statutory accounts as defined in Section 434 of the Companies Act 2006. The Group's statutory financial statements for the year ended 30 April 2009 have been filed with the Registrar of Companies. The auditor's report on those financial statements was unqualified and did not contain a statement under Section 498(2) of the Companies Act 2006.

2. Basis of preparation

These interim condensed consolidated financial statements are for the six months ended 31 October 2009. They have been prepared following the recognition and measurement principles of IFRS. They do not include all of the information required for full annual financial statements, and should be read in conjunction with the consolidated financial statements of the Group for the year ended 30 April 2009.

These financial statements have been prepared on the going concern basis, under the historical cost convention, except for the revaluation of certain financial instruments.

These condensed consolidated interim financial statements (the interim financial statements) have been prepared in accordance with the accounting policies adopted in the last annual financial statements for the year to 30 April 2009 except for the adoption of IAS 1 Presentation of Financial Statements (Revised 2007).

The adoption of IAS 1 (Revised 2007) does not affect the financial position or profits of the Group, but gives rise to additional disclosures. The measurement and recognition of the Group's assets, liabilities, income and expenses is unchanged, however fair value movements on available for sale investments that were recognised directly in equity are now recognised in other comprehensive income. IAS 1 (Revised 2007) affects the presentation of owner changes in equity and introduces a 'Statement of comprehensive income'.

The accounting policies have been applied consistently throughout the Group for the purposes of preparation of these condensed consolidated interim financial statements. 

3. Share issue

O11 August 2009 6,600,000 shares were issued at a premium of £0.191m. (31 October 2008.  On 16 June 2008 15,880,000 shares were issued at a premium of £21.3m On 29 July 2008 20,000 shares were issued at a premium of £5,000.  O8 September 2008 150,000 shares were issued at a premium of £43,000.)

4. Cash and cash equivalents

Unaudited

Unaudited

Audited

6 months

to 31

October

2009

6 months

to 31

October

2008

Year to

30 April

2009

£000

£000

£000

Cash at Bank

580

555

1,187

Proportion of cash in joint ventures interest

2,085

1,857

2,127

Bank balances

2,665

2,412

3,314

Cash and cash equivalents (which are presented as a single class of assets on the face of the balance sheet) comprise cash held by the Group and short-term Bank deposits with an original maturity of three months or less.

5. Earnings per share

The calculation of the basic earnings per share is based on the earnings attributable to ordinary shareholders divided by the weighted average number of shares in issue during the period.

The calculation of diluted earnings per share is based on the basic earnings per share, adjusted to allow for the issue of shares and the post tax effect of dividends and/or interest, on the assumed conversion of all dilutive options and warrants and other dilutive potential ordinary shares.

Reconciliations of the earnings and weighted average number of shares used in the calculations are set out below.

6 months to 31 October 2009

Earnings

Weighted

Average

number of

shares

Per share

amount

£000

Pence

Profit after tax

1,053

Earnings attributable to ordinary shareholders

Weighted average number of shares (used for basic earnings per share)

47,389,369

Dilutive effect of options and warrants

750,318

Diluted weighted average number of shares (used for diluted earnings per share)

48,139,687

Basic earnings per share

2.22p

Diluted earnings per share

2.19p

Year to 30 April 2009

Earnings

Weighted

average

number of

shares

Per share

amount

£000

Pence

Profit after tax

4,165

Earnings attributable to ordinary shareholders

Weighted average number of shares (used for basic earnings per share)

41,611,475

Dilutive effect of options and warrants

1,526,674

Diluted weighted average number of shares (used for diluted earnings per share)

43,138,149

Basic earnings per share

10.01p

Diluted earnings per share

9.65p

6 months to 31 October 2008

Profit after tax

544

Earnings attributable to ordinary shareholders

Weighted average number of shares (used for basic earnings per share)

39,508,727

Dilutive effect of options and warrants

1,616,926

Diluted weighted average number of shares (used for diluted earnings per share)

41,125,653

Basic earnings per share

1.38p

Diluted earnings per share

1.32p

6. Dividends

The dividends paid to equity shareholders over the past two years are set out below:

Year to 30 April 2008

£000's

Interim dividend

2.3p

633

14 January 2008

Final dividend

3.7p

1,607

15 September 2008

Total dividend

6.0p

2,240

Year to 30 April 2009

Final dividend

4.0p

1,886

15 October 2009

Total dividend

4.0p

1,886

7. Post balance sheet event - Acquisition of Sapphire Primary Care Developments Ltd

On 20 November 2009, Ashley House plc acquired Sapphire Primary Care Developments Ltd ("SPCD") from Admenta Holdings Ltd ("Lloyds Pharmacy"), the parent company of Lloyds Pharmacy one of the UK's largest community pharmacy operators, for a total consideration of £6.8m plus the value of work in progress. Under the terms of the Acquisition, Lloyds Pharmacy became a significant shareholder in Ashley House with approximately 10% of the enlarged equity.

Sapphire Primary Care Developments was established by Lloyds Pharmacy some 9 years ago as a developer of Primary Care premises and has been a competitor to Ashley House in the third party developer market. Its focus was naturally on opportunities where a significant on site pharmacy was available. Traditionally SPCD has sold the completed assets to property investment companies and the pharmacies have been operated by Lloyds Pharmacy. SPCD also became a minority investor in NHS LIFT and has shareholdings in 6 NHS LIFT companies which give it the opportunity to invest in new primary and community care facilities procured via NHS LIFT.

Immediately prior to the acquisition of SPCD by Ashley House, AH Medical Properties plc ("AHMP") acquired 4 properties (held in special purpose companies) valued at £11.8m from SPCD. Ashley House owns 6.7% of AHMP and acts as its asset manager.

SPCD consists of 13 personnel (including offices in Scotland and Coventry), a current pipeline of around 18 schemes, minority interests in 6 LIFT Cos and £1.45m in cash.

Of the 6 LIFT Co minority interests 3 are in Infracare LIFT Companies in BristolOxford and Dudley and are known to Ashley House and 3 are in GB Consortium in CoventryLiverpool and Barnet Enfield & Haringey.

Total consideration of £6.8m was payable as to:

£4.45m in new Ashley House shares

£0.35m in cash

Deferred cash consideration of £2 million payable to Lloyds Pharmacy as pipeline projects reach completion

A joint venture on new pharmacies has been established whereby Ashley House gets a 25% interest in all pharmacies delivered from its pipeline which will be set up and run by Lloyds Pharmacy.

Lloyds Pharmacy now hold approximately 10% of the share capital in Ashley House and Andrew Willetts, Lloyds Pharmacy FD has joined the Ashley House board as a non-executive director. These shares are the subject of a lock in agreement for 12 months followed by orderly market obligations.

Simultaneous with the acquisition, Ashley House also placed 2,387,000 new shares, with a nominal value of 1p each, for cash under existing authorities in a placing underwritten by the company's nominated adviser and broker Numis Securities Ltd at 75p per share. The proceeds of £1.8m will be used for working capital.

provisional pro-forma balance sheet reflecting the acquisition and placing is set out below for illustrative purposes only. However, the directors are still in the process of completing their valuation of the intangible assets acquired.

Group

31 October

2009

Sapphire

Acquisition

(*)

Placing

Post

Acquisition

Proforma

£000

£000

£000

£000

ASSETS

Non-current assets

Goodwill

270

-

-

270

Other intangible assets

24,800

3,750

-

28,550

Property, plant and equipment

194

-

-

194

Available for sale investments

1,079

1,600

-

2,679

Deferred tax asset

210

-

-

210

26,553

5,350

-

31,903

Current assets

Work in progress

1,402

-

-

1,402

Trade and other receivables

21,771

-

-

21,771

Cash and cash equivalents

2,665

1,200

1,790

5,655

25,838

1,200

1,790

28,828

Total assets

52,391

6,550

1,790

60,731

LIABILITIES

Current liabilities

Trade and other payables

(8,558)

(300)

(53)

(8,911)

Bank borrowings and overdrafts

(2,000)

-

-

(2,000)

Current income tax

(1,319)

-

-

(1,319)

(11,877)

(300)

(53)

(12,230)

Non-current liabilities

Bank borrowings

(2,127)

-

-

(2,127)

Deferred consideration

-

(2,000)

-

(2,000)

Total non-current liabilities

(2,127)

(2,000)

-

(4,127)

Total liabilities

(14,004)

(2,300)

(53)

(16,357)

Net assets

38,387

4,250

1,737

44,374

EQUITY

Share capital

478

55

24

557

Merger relief reserve

-

4,195

-

4,195

Share premium account

31,818

-

1,713

33,531

Share based payment reserve

614

-

-

614

Retained earnings

5,477

-

-

5,477

Total equity

38,387

4,250

1,737

44,374

(*) In accordance with section 612 of Companies Act 2006, the premium on the ordinary shares issued on acquiring 100% of the equity shares of Sapphire Primary Care Developments Limited is recorded to a merger relief reserve.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR UVRORRBAAUUR
Date   Source Headline
11th Dec 20205:30 pmRNSAshley House
11th Dec 20207:00 amRNSReverse Takeover Update and Administration
26th Aug 20201:27 pmRNSProposed Company Voluntary Arrangement
24th Aug 20207:00 amRNSProposed CVA – second adjournment of meeting
18th Aug 20201:05 pmRNSProposed CVA – adjournment of meeting
30th Jul 202012:25 pmRNSProposed CVA and potential Reverse Takeover
7th May 20205:25 pmRNSSale of Interests in PHL and LIFT
30th Mar 20201:59 pmRNSAdministration of F1 Modular and General Update
6th Mar 20207:30 amRNSSuspension - Ashley House Plc
6th Mar 20207:00 amRNSFinancial Update & Suspension of Trading
2nd Mar 202011:53 amRNSHolding(s) in Company
27th Feb 20207:00 amRNSTrading update & Withdrawal from NEX
31st Jan 20207:00 amRNSTrading Update
30th Jan 20201:45 pmRNSHolding(s) in Company
11th Dec 201911:01 amRNSAppointment of Non-executive director
10th Dec 201911:29 amRNSResult of Annual General Meeting
10th Dec 20197:00 amRNSAnnual General Meeting and Trading update
14th Nov 20197:00 amRNSYear End Change, Trading Update and Interim Report
7th Nov 20195:04 pmRNSDirectors' & PDMRs' Dealings
1st Nov 201910:10 amRNSHolding(s) in Company
30th Oct 20197:00 amRNSHolding(s) in Company
24th Oct 20192:23 pmRNSHolding(s) in Company
23rd Oct 20194:29 pmRNSHolding(s) in Company
21st Oct 20197:00 amRNSSale of Interest in Morgan Ashley
2nd Sep 20197:00 amRNSTrading Update
6th Aug 20197:00 amRNSDirectorate Change
5th Aug 20197:00 amRNSDirector/PDMR Shareholding
1st Aug 20192:05 pmRNSSecond Price Monitoring Extn
1st Aug 20192:00 pmRNSPrice Monitoring Extension
1st Aug 20197:00 amRNSTrading Update
5th Jul 20197:00 amRNSTrading Update
28th Jun 201911:51 amRNSHolding(s) in Company
25th Jun 20197:00 amRNSTrading Update
9th May 201910:19 amRNSDirector/PDMR Shareholding
9th May 20197:00 amRNSSchemes Update
3rd May 20191:21 pmRNSDirector/PDMR Shareholding
18th Feb 201912:56 pmRNSHolding(s) in Company
15th Feb 20192:53 pmRNSHolding(s) in Company
15th Feb 20192:50 pmRNSHolding(s) in Company
14th Feb 20194:41 pmRNSSecond Price Monitoring Extn
14th Feb 20194:35 pmRNSPrice Monitoring Extension
1st Feb 20191:38 pmRNSDirectors' & PDMRs' Dealings
31st Jan 20197:00 amRNSInterim Report
28th Jan 20199:40 amRNSAdditional Directorships - Andrew Willetts
16th Jan 201912:50 pmRNSChange of Accounting Year End
1st Nov 20187:00 amRNSDirectors' & PDMRs' Dealings
12th Sep 20181:08 pmRNSResult of AGM
16th Aug 20187:00 amRNSPreliminary Results
9th Aug 20187:00 amRNSJohn Moy
1st Aug 201811:34 amRNSDirectors' & PDMRs' Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.